Lista de obras -

(J)ALEX the great: a new era in the world of ALK inhibitors.

artículo científico publicado en 2018

A review of bevacizumab in the treatment of malignant pleural mesothelioma

artículo científico publicado en 2017

Antiangiogeneic Strategies in Mesothelioma

artículo científico publicado en 2020

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer

scientific article published on 08 April 2019

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

artículo científico publicado en 2018

Bevacizumab in advanced lung cancer: state of the art.

artículo científico

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

artículo científico

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors

artículo científico publicado en 2020

Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study

artículo científico publicado en 2020

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

scientific article published on 01 November 2018

Immunotherapy in relapsed mesothelioma

artículo científico publicado en 2018

Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation

artículo científico publicado en 2017

Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment

scientific article published on 27 July 2017

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial

artículo científico publicado en 2016

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

artículo científico publicado en 2019

Malignant pleural mesothelioma: 2013 state of the art

artículo científico publicado en 2013

Management of immune-related adverse events resulting from immune checkpoint blockade

scientific article published on 09 January 2019

Minimal Change Disease Induced by Lorlatinib

scientific article published on 01 August 2018

NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells

article

Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway

scientific article published in 2021

Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?

artículo científico publicado en 2015

RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome

scientific article published on 01 November 2019

Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC

artículo científico publicado en 2015

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report

scientific article published on 11 January 2019

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

scientific article published on 13 May 2019

Specific genomic alterations in high grade pulmonary neuroendocrine tumours with carcinoid morphology

artículo científico publicado en 2020

Trials of Prophylactic Irradiation of Tracts: What is the Appropriate End Point?

artículo científico publicado en 2019

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

scientific article published on 03 December 2019

[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives]

scientific article published on 01 February 2016

[Therapeutic advances in lung cancer]

artículo científico publicado en 2017

Lista de obras de

(J)ALEX the great: a new era in the world of ALK inhibitors.

A review of bevacizumab in the treatment of malignant pleural mesothelioma

Antiangiogeneic Strategies in Mesothelioma

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Bevacizumab in advanced lung cancer: state of the art.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors

Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Immunotherapy in relapsed mesothelioma

Lazarus Syndrome With Crizotinib in a Non-Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation

Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

Malignant pleural mesothelioma: 2013 state of the art

Management of immune-related adverse events resulting from immune checkpoint blockade

Minimal Change Disease Induced by Lorlatinib

NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells

Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway

Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter?

RET-Rearranged Lung Adenocarcinoma with Paraneoplastic Meige Syndrome

Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

Specific genomic alterations in high grade pulmonary neuroendocrine tumours with carcinoid morphology

Trials of Prophylactic Irradiation of Tracts: What is the Appropriate End Point?

Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study

[Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives]

[Therapeutic advances in lung cancer]